Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

BACKGROUND: Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1–, E2b–] targeting three TAAs—prostate-specific antigen (PSA), brachyury, and MUC-1—has been developed. Both brachyury and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilusic, Marijo, McMahon, Sheri, Madan, Ravi A, Karzai, Fatima, Tsai, Yo-Ting, Donahue, Renee N, Palena, Claudia, Jochems, Caroline, Marté, Jennifer L, Floudas, Charalampos, Strauss, Julius, Redman, Jason, Abdul Sater, Houssein, Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Schlom, Jeffrey, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993215/
https://www.ncbi.nlm.nih.gov/pubmed/33762322
http://dx.doi.org/10.1136/jitc-2021-002374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993215/
https://www.ncbi.nlm.nih.gov/pubmed/33762322
http://dx.doi.org/10.1136/jitc-2021-002374

Ejemplares similares